BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ashley DM, Riffkin CD, Lovric MM, Mikeska T, Dobrovic A, Maxwell JA, Friedman HS, Drummond KJ, Kaye AH, Gan HK, Johns TG, Hawkins CJ. In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. Br J Cancer 2008;99:294-304. [PMID: 18594532 DOI: 10.1038/sj.bjc.6604459] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Miles MA, Caruso S, Baxter AA, Poon IKH, Hawkins CJ. Smac mimetics can provoke lytic cell death that is neither apoptotic nor necroptotic. Apoptosis 2020;25:500-18. [PMID: 32440848 DOI: 10.1007/s10495-020-01610-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Thapa B, Kc R, Uludağ H. TRAIL therapy and prospective developments for cancer treatment. J Control Release 2020;326:335-49. [PMID: 32682900 DOI: 10.1016/j.jconrel.2020.07.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
3 Liu H, Su D, Zhang J, Ge S, Li Y, Wang F, Gravel M, Roulston A, Song Q, Xu W, Liang JG, Shore G, Wang X, Liang P. Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo. Sci Rep 2017;7:8953. [PMID: 28827692 DOI: 10.1038/s41598-017-09518-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
4 Castellino SM, Ullrich NJ, Whelen MJ, Lange BJ. Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. J Natl Cancer Inst 2014;106:dju186. [PMID: 25080574 DOI: 10.1093/jnci/dju186] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 9.1] [Reference Citation Analysis]
5 Calzolari A, Saulle E, De Angelis ML, Pasquini L, Boe A, Pelacchi F, Ricci-Vitiani L, Baiocchi M, Testa U. Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell lines. PLoS One. 2014;9:e94438. [PMID: 24740347 DOI: 10.1371/journal.pone.0094438] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
6 Jiguet Jiglaire C, Baeza-Kallee N, Denicolaï E, Barets D, Metellus P, Padovani L, Chinot O, Figarella-Branger D, Fernandez C. Ex vivo cultures of glioblastoma in three-dimensional hydrogel maintain the original tumor growth behavior and are suitable for preclinical drug and radiation sensitivity screening. Exp Cell Res 2014;321:99-108. [PMID: 24355810 DOI: 10.1016/j.yexcr.2013.12.010] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
7 Lim B, Scicchitano A, Beachler C, Gusani N, Sarwani N, Yang Z, Staveley-O'Carroll K, Ashkenazi A, Portera C, El-Deiry WS. FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. Cancer Biol Ther 2013;14:711-9. [PMID: 23792567 DOI: 10.4161/cbt.25310] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
8 Slipicevic A, Øy GF, Rosnes AK, Stakkestad Ø, Emilsen E, Engesæter B, Mælandsmo GM, Flørenes VA. Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis. Cancer Biol Ther 2013;14:146-54. [PMID: 23192275 DOI: 10.4161/cbt.22953] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
9 Xi G, Rajaram V, Mania-farnell B, Mayanil CS, Soares MB, Tomita T, Goldman S. Efficacy of vincristine administered via convection-enhanced delivery in a rodent brainstem tumor model documented by bioluminescence imaging. Childs Nerv Syst 2012;28:565-74. [DOI: 10.1007/s00381-012-1690-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
10 Beier D, Schulz JB, Beier CP. Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. Mol Cancer 2011;10:128. [PMID: 21988793 DOI: 10.1186/1476-4598-10-128] [Cited by in Crossref: 200] [Cited by in F6Publishing: 200] [Article Influence: 18.2] [Reference Citation Analysis]
11 Xi G, Mania-Farnell B, Rajaram V, Mayanil CS, Soares MB, Tomita T, Goldman S. Efficacy of interstitial continuous vincristine infusion in a bioluminescent rodent intracranial tumor model. J Neurooncol 2012;106:261-70. [PMID: 21842443 DOI: 10.1007/s11060-011-0680-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
12 Lovric MM, Hawkins CJ. TRAIL treatment provokes mutations in surviving cells. Oncogene 2010;29:5048-60. [PMID: 20639907 DOI: 10.1038/onc.2010.242] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 4.5] [Reference Citation Analysis]
13 Panner A, Crane CA, Weng C, Feletti A, Parsa AT, Pieper RO. A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res 2009;69:7911-6. [PMID: 19808964 DOI: 10.1158/0008-5472.CAN-09-1287] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
14 Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, McKinlay M, Benetatos CA, Condon SM, Chunduru SK, Yeoh G, Brink R, Vaux DL, Silke J. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol 2008;182:171-84. [PMID: 18606850 DOI: 10.1083/jcb.200801010] [Cited by in Crossref: 186] [Cited by in F6Publishing: 196] [Article Influence: 13.3] [Reference Citation Analysis]